Mark Labbett didn't mince his words during a recent episode of The Chase after a contestant defended her decision to play it safe. The 58-year-old quizzer, also known as "The Beast", delivered a ...

The Chase star Mark Labbett, also known as The Beast, has taken to social media to share his thoughts on new ITV gameshow ...

Mark Labbett viewers on Monday night’s The Chase ... The Chaser, nicknamed The Beast, was left visibly rattled after contestants Julie, Aaron, Elaine and Michael delivered a near-perfect ...

Viewers of Monday night’s edition of The Chase were left biting their nails after Chaser Mark Labbett, also known as 'The Beast', seemed to contemplate conceding defeat early in the broadcast on ...

The Chase fans accused Wednesday's ITV episode of featuring "fixed" questions that favoured Mark Labbett, sparking widespread ...

Semaglutide and tirzepatide aid weight loss by mimicking gut hormones Ozempic, Wegovy, Mounjaro and Zepbound treat diabetes, support weight loss The weight loss drugs differ in FDA-approved uses ...

After fans took notice of her new appearance, Trainor addressed her significant weight loss on Instagram, attributing her transformation to "huge lifestyle changes" such as using the weight-loss ...

How Does Semaglutide Work for Weight Loss? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Ozempic. Wegovy. Rybelsus. What do these medications have in common? They all contain ...

SaveHealth explores the historical trajectory of weight loss drugs, examining their scientific basis, regulatory battles, ...

Weight loss drugs are popular for helping patients quickly shed pounds Drugs like Ozempic are controversial for their side effects Side effects of some drugs can range from nausea to kidney ...

The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide). Participants taking Zepbound lost 50 pounds (lb) on average ...

May 12, 2025 – Turns out, two really is better than one – at least when it comes to weight loss drugs. In the first head-to-head trial of its kind, people with obesity who took tirzepatide ...